TY - JOUR
T1 - Human papillomavirus (HPV) vaccines in adults
T2 - Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
AU - Goldstone, Stephen E.
N1 - Funding Information:
for the qHPV vaccine clinical trials discussed in this commentary was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Medical writing assistance, under the direction of the author, was provided by Erin Bekes, PhD, and Derick Osakunor, PhD, of CMC AFFINITY, a division of IPG Health Medical Communications Ltd., in accordance with Good Publication Practice (GPP 2022) guidelines. This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding Information:
Medical writing assistance, under the direction of the author, was provided by Erin Bekes, PhD, and Derick Osakunor, PhD, of CMC AFFINITY, a division of IPG Health Medical Communications Ltd., in accordance with Good Publication Practice (GPP 2022) guidelines. This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Publisher Copyright:
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2023
Y1 - 2023
N2 - The risk for acquiring human papillomavirus (HPV) infections and associated diseases is lifelong. An important part of prophylactic HPV vaccine development is durable protection against infection and disease. With comprehensive long-term follow-up (LTFU) in adolescents, men, and women, the quadrivalent HPV (qHPV) vaccine demonstrated durable effectiveness, immunogenicity, and safety, with almost no breakthrough disease. Those who received a placebo during initial trials were offered the qHPV vaccine at study conclusion and continued to be followed in LTFU extensions. In this catch-up vaccination group, LTFU demonstrated protection even in individuals with current or prior HPV infection after approximately 3 years. The initial efficacy and durable long-term effectiveness of the qHPV vaccine have already translated to a real-world reduction in cancer and cancer precursors. To date, there is no evidence of waning protection; evidence suggests that vaccination ultimately provides strong protection against future disease, with effective prophylaxis even among those with past infections.
AB - The risk for acquiring human papillomavirus (HPV) infections and associated diseases is lifelong. An important part of prophylactic HPV vaccine development is durable protection against infection and disease. With comprehensive long-term follow-up (LTFU) in adolescents, men, and women, the quadrivalent HPV (qHPV) vaccine demonstrated durable effectiveness, immunogenicity, and safety, with almost no breakthrough disease. Those who received a placebo during initial trials were offered the qHPV vaccine at study conclusion and continued to be followed in LTFU extensions. In this catch-up vaccination group, LTFU demonstrated protection even in individuals with current or prior HPV infection after approximately 3 years. The initial efficacy and durable long-term effectiveness of the qHPV vaccine have already translated to a real-world reduction in cancer and cancer precursors. To date, there is no evidence of waning protection; evidence suggests that vaccination ultimately provides strong protection against future disease, with effective prophylaxis even among those with past infections.
KW - Adults
KW - effectiveness
KW - human papillomavirus
KW - long-term follow-up
KW - qHPV vaccine
UR - http://www.scopus.com/inward/record.url?scp=85150714680&partnerID=8YFLogxK
U2 - 10.1080/21645515.2023.2184760
DO - 10.1080/21645515.2023.2184760
M3 - Comment/debate
C2 - 36916016
AN - SCOPUS:85150714680
SN - 2164-5515
VL - 19
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 1
M1 - 2184760
ER -